Aspect Medical Systems Announces Positive Results Of BRITE Major Depression National Study

Aspect Medical Systems, Inc. (NASDAQ: ASPM) announced that study results from the BRITE (Biomarkers for Rapid Identification of Treatment Effectiveness) trial in major depression demonstrate that the company's EEG-based Antidepressant Treatment Response (ATR) indicator is a significant predictor of patient response and remission from depression when utilized one week following initiation of treatment with escitalopram.


The BRITE trial was conducted in collaboration with leading investigators from 10 facilities across the United States and enrolled more than 300 patients. Patient response was defined by researchers as a 50 percent improvement in depression symptoms as measured by the Hamilton Depression Rating Scale (HAM-D) after seven weeks of treatment, and remission was defined as recovery from depression (HAM-D